- Home
- AMRN vs CLLS Comparison
AMRN vs CLLS Comparison
Compare AMRN & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$13.99
HOLD
Current Price
$3.58
Company Overview
Basic Information| Metric | AMRN | CLLS |
|---|---|---|
| Founded | 1989 | 1999 |
| Country | Ireland | France |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 339.8M | 374.2M |
| IPO Year | 1998 | 2014 |
Fundamental Metrics
Financial Performance| Metric | AMRN | CLLS |
|---|---|---|
| Price | $13.99 | $3.58 |
| Analyst Decision | Strong Sell | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $12.00 | $8.50 |
| AVG Volume (30 Days) | ★ 82.1K | 32.4K |
| Earning Date | 05-19-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $181,104,000.00 | N/A |
| Revenue This Year | N/A | $40.37 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 39.22 | N/A |
| 52 Week Low | $0.35 | $1.10 |
| 52 Week High | $20.90 | $5.48 |
Technical Indicators
Market Signals| Indicator | AMRN | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 41.58 | 39.37 |
| Support Level | $13.65 | $3.41 |
| Resistance Level | $14.55 | $3.77 |
| Average True Range (ATR) | 0.75 | 0.17 |
| MACD | -0.10 | -0.02 |
| Stochastic Oscillator | 21.29 | 2.60 |
Price Performance
Historical Comparison AMRN
CLLS
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.